Equity
Retained Earnings
Kailera Therapeutics Retained Earnings decreased by 21.4% to -$447.53M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
Detailed definition
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
Peer comparison
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
Metric ID:
retained_earningsHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | -$368.67M | -$447.53M |
| QoQ Change | — | -21.4% |
Range-$447.53M – -$368.67M
Retained Earnings at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's retained earnings?
- Kailera Therapeutics (KLRA) reported retained earnings of -$447.53M in Q1 2026.
- What does retained earnings mean?
- The total accumulated profits the company has kept and reinvested rather than paying out as dividends.